Bristol Myers Squibb Announces Early Participation Results and Early Settlement of Tender Offers for Up to an Aggregate Purchase Price of Up to $4 0 Billion investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.
Biogen Inc.: Biogen Announces the Pricing Terms of Its Private Exchange Offer
CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) Biogen Inc. ( Biogen ) (Nasdaq: BIIB) today announced the pricing terms of its previously announced private offer to exchange (the Exchange Offer ) any and all of its outstanding 5.200% Senior Notes due 2045 (the Old Notes ), totaling $1.75 billion in aggregate principal amount, for a new series of 3.250% senior notes due 2051 to be issued by Biogen (the New Notes ) and cash on the terms and subject to the conditions set forth in the Offering Memorandum dated February 4, 2021 (the Offering Memorandum ) and the accompanying eligibility letter (the Eligibility Letter ), Canadian beneficial holder form and notice of guaranteed delivery (collectively, the Exchange Offer Documents ).
Biogen Announces the Pricing Terms of its Cash Tender Offer
CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the pricing terms of its previously announced offer to purchase for cash (the “Cash Offer”) its outstanding 5.200% Senior Notes due 2045 (the “Notes”), totaling $1.75 billion in aggregate principal amount, on the terms and subject to the conditions set forth in the Offer to Purchase dated February 4, 2021 (the “Offer to Purchase”) and the accompanying certification of eligibility to participate in the Cash Offer, the instructions for such certification and the notice of guaranteed delivery (collectively, the “Cash Offer Documents”).
Biogen Announces the Pricing Terms of Its Private Exchange Offer
CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the pricing terms of its previously announced private offer to exchange (the “Exchange Offer”) any and all of its outstanding 5.200% Senior Notes due 2045 (the “Old Notes”), totaling $1.75 billion in aggregate principal amount, for a new series of 3.250% senior notes due 2051 to be issued by Biogen (the “New Notes”) and cash on the terms and subject to the conditions set forth in the Offering Memorandum dated February 4, 2021 (the “Offering Memorandum”) and the accompanying eligibility letter (the “Eligibility Letter”), Canadian beneficial holder form and notice of guaranteed delivery (collectively, the “Exchange Offer Documents”).
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Biogen Announces the Pricing Terms of its Cash Tender Offer
Biogen Inc.February 10, 2021 GMT
CAMBRIDGE, Mass., Feb. 10, 2021 (GLOBE NEWSWIRE) Biogen Inc. (“Biogen”) (Nasdaq: BIIB) today announced the pricing terms of its previously announced offer to purchase for cash (the “Cash Offer”) its outstanding 5.200% Senior Notes due 2045 (the “Notes”), totaling $1.75 billion in aggregate principal amount, on the terms and subject to the conditions set forth in the Offer to Purchase dated February 4, 2021 (the “Offer to Purchase”) and the accompanying certification of eligibility to participate in the Cash Offer, the instructions for such certification and the notice of guaranteed delivery (collectively, the “Cash Offer Documents”).